Evidence map›Paper›PMID 23930163›Full record

ArticleInternational journal of preventive medicine2013

Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial.

Ahmad Shavakhi, Mohammad Minakari, Hassan Firouzian, Raheleh Assali, Azita Hekmatdoost, Gordon Ferns

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of preventive medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02764047 (Effect of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease), which is not on this map. Cited by 69 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 13 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02764047 naunknown statusnot on this mapstarted 2015, after this paper: background citation

Effect of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease

TypeinterventionalSponsorFederal University of Health Science of Porto AlegreRan2015 to 2018Enrolled58ConditionsNon-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver, Nonalcoholic, NAFLDArmsProbiotic
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 13 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.Computational and mathematical methods in medicine · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ahmad ShavakhiDepartment of Gastroenterology and Liver Disease, Isfahan University of Medical Science, Isfahan, Iran.
Mohammad Minakari
Hassan Firouzian
Raheleh Assali
Azita Hekmatdoost
Gordon Ferns
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic steatohepatitis (NASH) is a clinicopathological entity that is being recognized more frequently in recent years. This study aimed to evaluate the effects of Metformin, with and without a probiotic supplement on liver aminotransferases in patients with NASH.

methodsSixty four patients 18-75 years with NASH confirmed by biopsy and histological assessment were enrolled to study. Patients were randomized to one of the following treatments for 6 months: Group I, probiotic (Protexin two tablets per day) plus Metformin 500 mg two tablets per day (Met/Pro), or group II, Metformin 500 mg two tablets per day plus two placebo tablet (Met/P). After 6 month alanine aminotransferase (ALT), aspartate aminotransferase, and ultrasound grading of NASH were assessed.

resultsIN GROUP I, SERUM ALANINE AMINOTRANSFERASE (ALT: 133.7 ± 70 vs. 45.2 ± 32.5; P < 0.00), and aspartate aminotransferase activity (AST: 123.1 ± 72 vs. 44.2 ± 33.9; P < 0.001), and ultrasound grading of NASH (P < 0.001) all decreased significantly by the end of the treatment period. In group II, while serum alanine aminotransferase (ALT) was not significantly reduced (118.4 ± 67.9 vs. 112.5 ± 68.7; P < 0.064), aspartate aminotransferase activity (AST: 125.3 ± 71 vs. 113.4 ± 71; P < 0.001), and ultrasound grading of NASH did fall significantly (P < 0.01). Body mass index (BMI), fasting blood sugar (FBS), cholesterol, and triglyceride fell significantly in both groups.

conclusionsProbiotic combination with Metformin improves liver aminotransferases better than metformin alone in patients with NASH.

Indexed as

Aminotransferaseinsulin resistancenon-alcoholic fatty liver diseasenonalcoholic steatohepatitisprobioticrandomized clinical trial

Identifiers

PMID23930163
PMCPMC3733183
OpenAlexW1746600962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.